The Company
Drug Development
Debiopharm Innovation Fund
- At a Glance
- Approach
- Portfolio
- News
- Team
- Contact
Manufacturing, Research & Development

Awards & Grants
Corporate Responsibility
Careers
Press Releases
Media
Manage cookies
Our parent company

Contact us

Home Drug Development Publications

Publications

Filters (1)

AbYlink afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0432 Debio 0614 (istaroxime) Debio 0719 Debio 0932 NSCLS Debio 1124 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1347 Debio 1452 Debio 1453 Debio 1561 Debio 1562 Debio 1562M Debio 4126 Debio 8609 Sanvar Debio 9902 - ZT-1 EPI-hNE4 FibroTrap fuze Heparins Huperzine-A Multilink naratuximab emtansine (Debio 1562) nucleai Oxaliplatin PLGA Triptorelin xevinapant

April 10, 2024

Identification of Debio 0432 as a potent and selective USP1 Inhibitor for Cancer Therapy

Legal Notice
Code of Conduct
Manage cookies
Privacy Policy
Terms & Conditions

© 2024 Debiopharm Made with passion by

Made it with passion